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T WO important components of general anesthesia are hypnosis and analgesia: The hypnotic component 
may be defined as probability of tolerance to a nonnoxious 
stimulus (e.g., name calling or shake and shout), whereas 
the analgesic component (also called: the balance between 
nociception and antinociception) may be considered as the 
probability of tolerance to a noxious stimulus.1 Tolerance 
means “the absence of a response” being either a somatic 
response (e.g., movement, sweating, eye opening), a hemo-
dynamic response (increase in heart rate or blood pressure), 
or an arousal on the electroencephalogram of the frontal 
cortex, which is a reflection of a decreased cerebral hypnotic 
drug effect due to an insufficient analgesic effect. This “com-
ponent” definition is based on the notion that tolerance to 
verbal and noxious stimulation will be mediated through 
different neuronal networks, which are located in the higher 
cortical versus subcortical structures of the brain, respec-
tively.1 These networks are independently affected by the 
interaction between a hypnotic and an analgesic drug. As 
an example of this, Heyse et al.2 showed different response 
surface models for tolerance to nonnoxious and noxious 
stimulation.
What We Already Know about This Topic
•	 Continuous	 neurophysiologically	 derived	 measures	 of	 hyp-
notic	or	analgesic	effect	are	influenced	by	interaction	between	
hypnotic	and	analgesic	drugs
•	 The	 interaction	 between	 sevoflurane	 and	 remifentanil	 on	
	nonnoxious	 and	 noxious	 dichotomous	 effect	 endpoints	 was	
synergistic
What This Article Tells Us That Is New
•	 The	 opioid	 effect	 on	 electroencephalography-derived	 vari-
ables	was	very	weak
•	 The	effects	of	sevoflurane	and	remifentanil	on	the	hypnotic	ef-
fect	measured	by	bispectral	 index	or	entropy	were	additive,	
but	they	acted	synergistically	on	Composite	Variability	Index
•	 Painful	stimulation	 increased	 the	C50	of	sevoflurane	without	
changing	the	structural	models	for	bispectral	index	and	entro-
py;	a	more	complex	parameter	shift	was	found	for	Composite	
Variability	Index
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ABSTRACT
Background: The authors studied the interaction between sevoflurane and remifentanil on bispectral index (BIS), state 
entropy (SE), response entropy (RE), Composite Variability Index, and Surgical Pleth Index, by using a response surface 
methodology. The authors also studied the influence of stimulation on this interaction.
Methods: Forty patients received combined concentrations of remifentanil (0 to 12 ng/ml) and sevoflurane (0.5 to 3.5 vol%) 
according to a crisscross design (160 concentration pairs). During pseudo–steady-state anesthesia, the pharmacodynamic 
measures were obtained before and after a series of noxious and nonnoxious stimulations. For the “prestimulation” and “post-
stimulation” BIS, SE, RE, Composite Variability Index, and Surgical Pleth Index, interaction models were applied to find the 
best fit, by using NONMEM 7.2.0. (Icon Development Solutions, Hanover, MD).
Results: The authors found an additive interaction between sevoflurane and remifentanil on BIS, SE, and RE. For Compos-
ite Variability Index, a moderate synergism was found. The comparison of pre- and poststimulation data revealed a shift of 
C50SEVO for BIS, SE, and RE, with a consistent increase of 0.3 vol%. The Surgical Pleth Index data did not result in plausible 
parameter estimates, neither before nor after stimulation.
Conclusions: By combining pre- and poststimulation data, interaction models for BIS, SE, and RE demonstrate a consistent 
influence of “stimulation” on the pharmacodynamic relationship between sevoflurane and remifentanil. Significant population 
variability exists for Composite Variability Index and Surgical Pleth Index. (Anesthesiology 2014; 120:1390-9)
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In addition to the dichotomous observations of toler-
ance to stimulation, several neurophysiology-derived mea-
sures of anesthesia effect have been developed to monitor the 
anesthesia state of the patient in a continuous way. Electro-
encephalographic measures, such as bispectral index (BIS; 
Covidien, Boulder, CO), state entropy (SE), and response 
entropy (RE) (M-Entropy; GE Healthcare, Helsinki, Fin-
land), have a stronger correlation with the hypnotic com-
ponent than with the analgesic component of anesthesia.3 
More recently, new continuous measures with different neu-
rophysiological background, such as the Surgical Pleth Index 
(SPI; GE Healthcare) and the Composite Variability Index 
(CVI; Covidien), attempt to quantify the balance between 
nociception and antinociception.4,5 All these continuous 
surrogate measures of hypnotic or analgesic effect are influ-
enced by the interaction between hypnotic and analgesic 
drugs and should therefore be studied with this multidrug 
reality in mind. Eventually, the ultimate goal of continuous 
monitoring is to effectively counter deviating measurements 
with an adequate change in the balance between opioids and 
hypnotics so that better clinical results are obtained. This 
performance can only be expected if a well-described dose–
response relationship exists between the measurements and 
the applied drug combinations.
To depict this dose–response relationship in the presence 
of multiple drugs, it is common to use population-derived 
response surface interaction models.2 For BIS, SE, RE, CVI, 
and SPI, the interaction between sevoflurane and remifent-
anil on continuous measures has not yet been described.
Therefore, the primary goal of this study was to develop 
response surface models that best describe the dose–response 
relationship between the combined administration of sevo-
flurane and remifentanil versus BIS, SE, RE, CVI, and SPI. 
Overall, we hypothesized that the nature of the various inter-
actions should be synergistic for the continuous measures as 
this is in concordance with the interaction on dichotomous 
clinical endpoints as described by Heyse et al.2 The second-
ary goal of the study was to investigate whether noxious 
stimulation significantly affects the model structure or the 
model parameters.
Materials and Methods
The data presented in this article were collected during a pre-
vious study as published by Heyse et al.2 This study presents 
the results of a secondary analysis focusing on the continu-
ous measurements of drug effect, whereas the previous study 
focused on dichotomous endpoints of anesthetic effect (clini-
cal signs of responsiveness). The studied patients, the criss-
cross study design, and drug administration methods applied 
in this study have been described elsewhere in detail.2
Subjects
After obtaining Institutional Review Board (Ghent  University 
Hospital Ethics Committee, Gent, Belgium) approval 
and prospective trial registration at ClinicalTrials.gov 
(NCT00522587) and after obtaining written informed con-
sent, 40 patients with American Society of Anesthesiologists 
status I or II, aged 18 to 60 yr, and scheduled to undergo 
surgery requiring general anesthesia were included. Exclu-
sion criteria were weight less than 70% or more than 130% 
of ideal body weight, neurological disorders, diseases involv-
ing the cardiovascular system, pulmonary diseases, gastric 
diseases, endocrine diseases, and recent use of psychoac-
tive medication or use of more than 20 g of alcohol daily. 
The complete study was executed in a quiet operating room 
before the start of the surgical procedure.
Study Design
This study was performed as a randomized, prospective, 
open-label study. No participant of the study received 
premedication. After the patients arrived in the operating 
room, standard monitors (electrocardiogram, noninva-
sive blood pressure, and hemoglobin oxygen saturation), 
M-Entropy using a Datex S/5 Anesthesia Monitor (GE 
Healthcare), and BIS using an Aspect A-2000 monitor 
(Covidien) were connected, and a large forearm vein was 
cannulated. Thereafter, the patients were preoxygenated 
with 6 l/min of O2 at an FI = 1.0 for 5 min using a tight-
fitting face mask, which also served to sample exhaled air 
for end-tidal carbon dioxide measurement. Vital signs and 
end-tidal sevoflurane concentrations, respiratory data (tidal 
volume, minute volume, and end-tidal carbon dioxide), 
and infusion-related data (predicted concentrations and 
infused volumes) were continuously recorded on a com-
puter hard disk using RUGLOOP II data-recording soft-
ware (Demed, Temse, Belgium).
Drug Administration
Technical Aspects. Remifentanil was administered by a tar-
get-controlled infusion technique by using  RUGLOOP II 
TCI software (Demed) based on a three-compartment 
model with an effect-site compartment as published by 
Minto et al.6,7 Sevoflurane was administered in 50% O2 and 
50% air by using a standard out-of-circle vaporizer and a 
standard breathing circuit of an ADU anesthesia workstation 
(Datex/Ohmeda; GE Healthcare).
Dosing Regimen. We randomized 40 patients to receive 
four prespecified combinations of sevoflurane (0.5 to 3.5 
vol%) and remifentanil (0 to 12 ng/ml) according to a mod-
ification of the crisscross design proposed by Short et al.8 
In half of the patients, remifentanil was held constant, and 
sevoflurane was stepwise increased; in the other half, sevo-
flurane was held constant and remifentanil was stepwise 
increased. The dosing schedule is shown in table 1 in the 
study by Heyse et al.2 No muscle relaxants were adminis-
tered throughout the study.
Assessment of Clinical Response
For each concentration step, the clinical response was 
assessed 12 min after reaching the target concentrations to 
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allow for plasma effect-site equilibration. The patient was 
exposed to the following series of stimuli, with increasing 
intensity: (1) verbal and nonpainful tactile stimuli accord-
ing to the Modified Observer’s Assessment of Alertness/
Sedation (OAA/S) score9; (2) a tetanic stimulus of the 
ulnar nerve for 5 s by using the standard neurostimula-
tor; (3) insertion of a laryngeal mask airway (size 3 for 
women and 4 for men, LMA Unique® [The Surgical Com-
pany, Amersfoort, The Netherlands]); and (4) laryngoscopy 
aiming at full visualization of the vocal cords by using a 
size-3 curved  Macintosh-type blade (HEINE Optotechnik 
GmbH & Co KG, Herrsching, Germany). All stimuli—
including laryngoscopy—were performed by a single anes-
thesiologist (B.H.) to minimize interindividual variability 
in stimulation. Between each stimulus, a 1-min delay was 
maintained to evaluate the somatic responsiveness on each 
stimulus. If there was no response to a stimulus, the next 
stimulus was applied 1 min after the response assessment of 
the previous stimulus.
In this study, we only compared data before OAA/S score 
(unstimulated state) with data after laryngoscopy (stimu-
lated state). For the data that were obtained in between 
stimuli, we did not estimate separate models. We could not 
exclude a bias evoked by influences of the preceding stimu-
lus on the next one. However, by performing simultaneous 
model estimations on data before and after the sequence of 
four clinically relevant stimulations, we explore pharmaco-
dynamic differences between a generally “unstimulated” ver-
sus a “stimulated” anesthesia state.
Data Acquisition and Management
BIS, SE, and RE. The spectral entropy monitor (M-Entropy; 
GE Healthcare) calculated SE and RE. BIS was simulta-
neously derived from the frontal electroencephalogram 
 (At-Fpzt) by using a quatro BIS™ sensor with four elec-
trodes (Covidien). The smoothing time of the BIS monitor 
was set at 15 s. All data were recorded electronically using 
RUGLOOP II software (Demed) with a 5-s time interval.
The median of the recorded values during 1 min before 
the assessment of the OAA/S score was used for the analysis 
of the BIS, SE, and RE data.
CVI. The raw electroencephalographic signal was captured 
by the BIS™ monitor with a 128-Hz sample rate and 
allowed post hoc calculation of CVI. The calculation of CVI 
has been described by Mathews et al.5 The CVI is a compos-
ite index that combines the variability in BIS with frontal 
electromyographic changes over time. A high CVI reflects 
activation of the frontal electromyography and increased 
input of sensory information from deep brain structures 
to the cortex. A low CVI reflects an adequate inhibition 
of this sensory input and adequate analgesia. The CVI 
was calculated with a 5-s time interval. The median of the 
recorded values during 1 min before the assessment of the 
OAA/S score was used for the analysis. In the case that one 
or more values were missing during the last minute before 
the assessment of OAA/S score due to a technical reason, 
the CVI was regarded as a missing value and was not taken 
into account in the analysis.
SPI. The SPI is derived from plethysmographic pulse wave 
characteristics combined with heart rate variability and is a 
surrogate measure of the orthosympathetic and parasympa-
thetic nervous system response to noxious stimulation. The 
calculation of SPI has been described by Huiku et al.4 The 
SPI was calculated with a 1-s time interval. The median 
of the recorded values during 1 min before the assessment 
of the OAA/S score was used for the analysis. In the case 
that there were less than seven values during the last min-
ute before the assessment of OAA/S score, the SPI was 
regarded as a missing value and was not taken into account 
in the analysis.
Data after Stimulation. A moving median technique was 
applied on the raw data measured during 1 min after laryn-
goscopy. For the NONMEM analysis, the highest value 
of the moving median over several consecutive values was 
used. By doing so, the effect of single outlier values on 
the average behavior of each measurement was minimized 
without losing sensitivity for detecting a relevant response 
on BIS, SE, RE, CVI, and SPI after stimulation. For mea-
surements that were logged every 5 s (BIS, SE, RE, and 
CVI), or every second (SPI), we performed the moving 
median technique over a sequence of respectively five or 
seven consecutive values. In the case that there were less 
than five or seven consecutive values during 1 min after 
application of laryngoscopy, or if laryngoscopy was not 
applied because the patient was responsive to a previous 
stimulus (see the study by Heyse et al.2), the measurement 
was considered as missing and was not taken into account 
in the analysis.
Pharmacodynamic Analysis of the Continuous Variables
For the continuous data, a negative sigmoid Emax model was 
used10:
 
Effect REST= − −( )⋅
+



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U
U
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γ
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 (1)
where E0 is the baseline value in the absence of drug, REST 
is a nonsuppressible effect (the lowest possible value of the 
effect variable), U represents the normalized combined 
potency of one or more drugs, and γ is the slope param-
eter reflecting the steepness of the concentration–effect 
relationship.
The normalized combined potency U is a function of 
the drug effect-site concentrations and model parameters, as 
described in detail in the appendix in the study by Heyse 
et al.2 The following models were tested:
a. Greco model
U
C
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where CSEVO is the effect-site concentration of sevoflu-
rane, CREMI is the effect-site concentration of remifentanil, 
C50SEVO is the effect-site concentration of sevoflurane with 
50% effect, C50REMI is the effect-site concentration of remi-
fentanil with 50% effect, and α is a dimensionless interac-
tion parameter.
b. Reduced Greco model without effect of the opioid alone
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c. Minto model11
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where βU50 is a dimensionless interaction parameter, and θ 
is defined by:
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d. Hierarchical model
 
U
C
C
C
C
o
SEVO
SEVO
REMI
REMI
= ⋅ +
 



50 1 50
γ
 
(6)
where γO is the slope parameter reflecting the steepness of 
the concentration–effect relationship for remifentanil.
Because each pharmacodynamic endpoint was analyzed 
separately, the Scaled C50O and Fixed C50O Hierarchical 
models are identical.2
For BIS, SE, and RE, it was assumed that the measure 
approaches zero for high concentrations of sevoflurane or 
remifentanil, so REST is zero, reducing the model to a frac-
tional Emax model.
10 For CVI and SPI, the nonsuppressible 
effect REST was modeled as a function of the drug concentra-
tions according to the procedure described by Minto et al.11:
 
REST REST RESTSEVO REMI
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(7)
where RESTSEVO, RESTREMI, and βREST are model 
parameters.
Parameter Estimation
The model parameters were estimated using NONMEM 
7.2.0 (Icon Development Solutions, Hanover, MD), using 
first-order conditional estimation. Platform was Windows 
XP (Microsoft, Redmond, WA) and compiler was G95. 
For all parameters, interindividual variability was assumed 
either to be absent or to have a lognormal distribution. It 
was tested whether a single value for the individual devia-
tion from the typical value (eta in NONMEM) could be 
used for C50 of sevoflurane and remifentanil, in accor-
dance with the assumption that this value reflects the sen-
sitivity of that individual for hypnotic and opioid drugs. 
Residual intraindividual variability of the continuous vari-
ables was modeled using standard additive or proportional 
error models.
Parameters were tested for significance by comparing the 
objective function which is minus two times log-likelihood 
(−2LL). Significance level for hypothesis tests was 0.01 
 (chi-square test), or a 6.84 difference in the −2LL adding 
one parameter for nested models. The goodness-of-fit for 
the models was also assessed by visual inspection of the pre-
dicted versus observed plots and the distribution of residuals 
for each of the continuous endpoints.
Model building was performed starting with the sim-
plest form of each model and expanding the model with 
parameters and interindividual variability until the decrease 
of the objective function value was not statistically signifi-
cant using the chi-square test. In addition, model build-
ing was started with the most complex model, reducing 
the model by fixing parameters to zero. The NONMEM 
analysis was performed with various values for initial esti-
mates and boundary values. The results were accepted as 
valid only if both minimization and covariance steps were 
successful, unless stated otherwise.
To evaluate the final model, a bootstrap analysis was per-
formed, based on 2,000 sets of 40 patients each, randomly 
selected from the available 40 patients, using a custom pro-
gram written in c. Results were analyzed in Excel (Microsoft) 
to obtain nonparametric 95% CIs.
The poststimulation data after laryngoscopy were ana-
lyzed by using an identical modeling approach as applied 
on the prestimulation data. To investigate the effect of the 
stimulations on the model parameters, we performed a 
simultaneous fitting of the data before OAA/S (= unstimu-
lated anesthesia state) and after laryngoscopy (= stimulated 
anesthesia state) in a stepwise model-building process, start-
ing with fixed common parameters for both data sets, fol-
lowed by testing the addition of parameters for the difference 
between before OAA/S and after laryngoscopy.
Statistical Analysis
All model parameters are reported as typical values with 
relative standard error (in % of the typical value) within 
parentheses, and clinical data are given as mean and SD or as 
median and range, when appropriate.
Results
In total, 40 patients (26 women and 14 men) were included 
in this study. The demographics are as follows: body weight, 
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66 ± 11 kg; height, 172 ± 8 cm; and age, 30 ± 11 yr. All patients 
were classified as American Society of Anesthesiologists status I.
Data
In total, the data sets contained 159 periods of testing (40 
patients with 4 periods per patient minus 1 missing period 
where no stimulus was given).
Model Development for BIS
Initially, BIS data were analyzed using the Greco, Reduced 
Greco, Minto, and Hierarchical models, using a fractional 
Emax model (REST = 0). For both the Greco model and the 
Minto model, the interaction term for C50 did not dif-
fer significantly from zero. Similarly, the interaction term 
for γ in the Minto model did not differ significantly from 
zero. Consequently, both models yield identical results. 
The objective function value for the Greco model (808.5) 
was markedly lower than that for the Reduced Greco 
model (823.0) and Hierarchical model (822.2), and there-
fore, the Greco model was considered as the most appro-
priate method. The additional error model fitted better to 
the data than the proportional error model, as concluded 
from the objective function value and diagnostic plots of 
residuals.
Final Model for BIS
The final results for this model are shown in table 1. In 
the final model, interindividual variability was included in 
C50REMI and C50SEVO with a common eta. The value for 
C50 for remifentanil (27.3 ng/ml) exceeds the upper range 
of concentrations in the study (12 ng/ml), but its precision 
was satisfactory (relative standard error 12%).
The response surface of the final model is shown in 
figure 1. Figure 2 depicts the observed BIS values (filled 
symbols) and predicted BIS (solid line) versus the normal-
ized combined potency UBIS, which has a sigmoidal Emax 
relationship.
Model Development for SE and RE
The Greco model was found to be the most appropriate 
model for SE and RE, in accordance with the best model 
for BIS.
Final Models for SE and RE
The results of the final models are summarized in table 1. 
The variability in SE and RE is larger than for the BIS data, 
as reflected in larger relative standard errors, larger interindi-
vidual variability, and larger residual SD.
The response surfaces of the final models for SE and RE 
are shown in figure 1. Figures 3 and 4 depict the observed 
(filled symbols) and predicted (solid line) SE and RE versus 
the normalized combined potencies USE and URE, respec-
tively, which also have a sigmoidal Emax relationship.
Model Development for CVI
In four patients, the CVI could not be calculated due to miss-
ing data. In 17 patients, the CVI could not be calculated from 
the available electroencephalogram registration in one or more 
periods. In total, 122 CVI values in 36 patients were available.
Table 1. Population Model Estimates for BIS, SE, RE, and CVI
BIS SE RE CVI
Interaction Model Greco/Minto Greco/Minto Greco/Minto Reduced Greco
C50REMI (ng/ml) 27.3 (13%)
(20.4–37.7)
16.2 (19%)
(11.0–27.9)
18.2 (21%)
(12.6–31.9)
7.56 (32%)
(4.01–17.7)
C50SEVO (vol%) 1.99 (6%)
(1.68–2.23)
1.82 (8%)
(1.49–2.11)
1.88 (7%)
(1.58–2.14)
1.09 (97%)
(0.08–3.28)
  γ 1.88 (10%)
(1.53–2.27)
1.87 (9%)
(1.54–2.26)
2.08 (8%)
(1.76–2.40)
1.16 (29%)
(0.77–2.15)
  E0 89.5 (4%)
(83.5–99.1)
97.1 (5%)
(84.3–110)
103 (4%)
(95–113)
4.32 (57%)
(2.35–19.9)
IIV(C50REMI) 20% (14%)
(14–25%)
59% (19%)
(33–86%)
67% (19%)
(43–99%)
0*
IIV(C50SEVO) 20%† 22% (22%)
(8–30%)
25% (19%)
(13–34%)
18% (24%)
(0–26%)
Residual SD 6.2‡ (9%)
(5.0–7.2)
9.5‡ (10%)
(7.5–11.1)
9.6‡ (10%)
(7.5–11.2)
27%§ (11%)
(22–33%)
∆C50SEVO (vol%) 0.30 (18%)
(0.20–0.41)
0.31 (22%)
(0.18–0.46)
0.36 (20%)
(0.23–0.52)
‖
Values are typical values, relative standard error (% of the typical value) and 95% CI obtained by bootstrapping.
* Not significantly different from zero; † Common value for remifentanil and sevoflurane; ‡ Additive error; § Proportional error; ‖ Could not be estimated (for 
details, see text). 
BIS = bispectral index; CVI = Composite Variability Index; C50REMI = effect-site concentration of remifentanil with 50% effect; C50SEVO = effect-site concen-
tration of sevoflurane with 50% effect; ΔC50SEVO = increase of C50SEVO after laryngoscopy, as obtained in a separate analysis (see text); E0 = baseline value 
in the absence of drugs; γ = model parameter reflecting the steepness of the concentration–effect relationship; IIV(C50REMI) and IIV(C50SEVO) = interindividual 
variability for C50REMI and C50SEVO, respectively (calculated as the square root of interindividual variance, multiplied by 100%); Residual SD = SD of the dif-
ferences between the observed and predicted responses (calculated as the square root of the residual variance); RE = response entropy; SE = state entropy.
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For CVI, the objective function value of the Reduced 
Greco model was lower than for the Greco model and 
Minto model. The proportional error model fitted better to 
the data than the additional error model, as concluded from 
the objective function value and diagnostic plots of residuals. 
Using the Hierarchical model, the slope factor γ for remi-
fentanil (0.289) and C50SEVO (0.266 vol.%) was very low, 
E0 (10.2) was much higher than the highest observed CVI 
Fig. 1. Response surface for electroencephalographic endpoints before stimulation (A, C, E, G) and after stimulation (B, D, F, H) 
was applied: Bispectral index (BIS), state entropy (SE), response entropy (RE), and Composite Variability Index (CVI), as a function 
of the end-tidal steady-state sevoflurane concentration and the predicted remifentanil effect-site concentration, calculated from 
the data listed in table 1. Measured values above the surface are shown as filled circles and below the surface as open circles.
Fig. 2. Relationship between the normalized combined po-
tency UBIS according to the Greco model and the observed 
bispectral index (BIS) (squares, n = 159) and predicted BIS 
(solid line; calculated from the data listed in table 1) for un-
stimulated (filled symbols) and stimulated (open symbols).
Fig. 3. Relationship between the normalized combined po-
tency USE according to the Greco model and the observed 
state entropy (SE) (squares, n = 159) and predicted SE (solid 
line; calculated from the data listed in table 1) for unstimu-
lated (filled symbols) and stimulated (open symbols).
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value, and standard errors were high; therefore, this model 
was not accepted as a valid model.
Final Model for CVI
The results for the final Reduced Greco model are shown in 
table 1. The residual error of 27% is large and the CIs for the 
model parameters are wide, reflecting the poor fit.
The response surface of the final model for CVI is shown 
in figure 1. Figure 5 depicts the observed (filled symbols) 
and predicted CVI values (solid line) versus the normalized 
combined potency UCVI. The CVI has a sigmoidal Emax rela-
tionship with UCVI, which is comparable in behavior to BIS, 
SE, and RE.
Model Development for SPI
In two patients, the SPI could not be calculated due to miss-
ing data. In four patients, the SPI could not be calculated 
from the available plethysmography data in one or more 
periods. In total, SPI data from 145 periods in 38 patients 
were available.
Modeling of the SPI data did not result in reliable results. 
Plotting the SPI data against the sevoflurane or remifentanil 
concentration revealed that the SPI value is hardly affected 
by sevoflurane or remifentanil, in contrast to the BIS, SE, 
RE, and CVI (data not shown).
Data after Stimulation
The data after stimulation were first analyzed using an identi-
cal modeling approach as applied on the unstimulated data. 
For BIS, SE, and RE, the number of data points was 114 (in 
45 periods, laryngoscopy was not applied for ethical or other 
reasons). The optimal models were identical and the param-
eters were broadly comparable with the results before the 
assessment of OAA/S, except for C50SEVO, which was consis-
tently higher after the series of stimulation (data not shown).
Next, to investigate this effect of stimulation on the 
model parameters, we performed a simultaneous fitting of 
the data before OAA/S (= unstimulated anesthesia state) and 
after laryngoscopy in a model-building process (= stimulated 
anesthesia state), starting with fixed common parameters for 
both data sets, followed by adding parameters for the dif-
ference between before OAA/S and after laryngoscopy. This 
analysis revealed that C50SEVO was significantly higher after 
laryngoscopy for BIS, SE, and RE, with an average increase 
of 0.3 vol% sevoflurane (table 1), whereas the other param-
eters did not change. The response surfaces of the final mod-
els for BIS, SE, and RE are shown in figure 1. Figures 2–4 
depict the observed values (open symbols) and predicted 
values (solid line) versus the normalized combined potency 
U for BIS, SE, and SE, respectively. Because the baseline 
values, maximal effect and steepness of the model are not 
affected by the stimulation, the relationship between U and 
predicted value is not affected, and the solid line is iden-
tical for unstimulated and stimulated conditions. For each 
combination of sevoflurane and remifentanil, the value UBIS 
(similar for USE and URE) after stimulation is lower com-
pared with the unstimulated state as a result of the higher 
C50SEVO. Consequently, the predicted BIS after stimula-
tion will be higher than in the unstimulated state, reflecting 
a reduction of the combined drug effect. In other words, 
stimulation moves UBIS to the left, and the predicted BIS 
upwards along the solid lines of figures 2–4.
In contrast, simultaneous analysis of the CVI data before 
OAA/S and after laryngoscopy, with parameters fixed to the 
values from the analysis of the data before OAA/S alone 
(table 1), resulted in a lower value for C50REMI (3.09 ng/ml; 
CI, 1.78 to 4.68 ng/ml), a higher value for γ (1.62; CI, 1.28 
to 1.79), and E0 (13.1; CI, 9.4 to 17.2). Also, the residual SD 
(46%; CI, 37 to 53%) after stimulation was higher, indicat-
ing an even larger variability in the dose–response relationship 
of CVI compared with the unstimulated condition. Figure 5 
depicts the observed values (open symbols) and predicted CVI 
(dashed line) versus the normalized combined potency UCVI, 
respectively. Figure 5 also shows the shift in dose–response 
relationship of CVI versus UCVI between the unstimulated 
Fig. 4. Relationship between the normalized combined po-
tency URE according to the Greco model and the observed 
response entropy (RE) (squares, n = 159) and predicted RE 
(solid line; calculated from the data listed in table 1) for un-
stimulated (filled symbols) and stimulated (open symbols).
Fig. 5. Relationship between the normalized combined po-
tency UCVI according to the Reduced Greco model and the 
observed Composite Variability Index (CVI) (squares, n = 122) 
and predicted CVI (lines; calculated from the data listed in 
table 1) for unstimulated (filled symbols, solid line) and stimu-
lated (open symbols, dashed line).
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(solid line) and stimulated condition (dashed line). Because 
the baseline and steepness are affected by the stimulation, the 
relationship between UCVI and predicted value is different for 
the unstimulated and stimulated data. The response surface 
for CVI after stimulation is shown in figure 1.
The SPI data after stimulation (104 valid SPI values) were 
analyzed using the same approaches. Similar to the unstim-
ulated data, the SPI values after stimulation were hardly 
affected by sevoflurane or remifentanil, and modeling did 
not result in reliable results (data not shown).
Isoboles
In figure 6, the isoboles of BIS values from 10 to 80 are 
depicted for the unstimulated (solid lines) and stimulated 
(dashed lines) condition. The additive nature of the interac-
tion results in linear isoboles for the complete range of BIS 
values. The isoboles are shifted upwards after stimulation, 
reflecting the increase in C50SEVO.
In figure 7, the isoboles of CVI values from 0.5 to 3 are 
depicted for the unstimulated (solid lines) and stimulated 
(dashed lines) condition, showing a synergistic nature of the 
interaction, as reflected by the Reduced Greco model. For 
low CVI values, the isoboles of the stimulated condition 
intersect the isoboles of the unstimulated condition.
For SPI, no isoboles could be depicted, as we could not fit 
an appropriate response surface model to the data.
Discussion
We describe the interaction between sevoflurane and remi-
fentanil on BIS, SE, RE, CVI, and SPI. Although opioids 
have a rather weak effect on the electroencephalogram, we 
found an additive effect of remifentanil on reduction of BIS, 
SE, and RE by sevoflurane. The effect on CVI was synergis-
tic. The SPI was not affected by sevoflurane or remifentanil. 
The Greco model provided the best fit of the data for BIS, 
SE, and RE, whereas the reduced Greco model best described 
CVI. Interestingly, the structural interaction model was not 
affected by noxious stimulation, but noxious stimulation did 
increase the C50sevo for BIS, SE, and RE by 20%, whereas 
the C50REMI did not change. In contrast, for CVI all model 
parameters changed except C50SEVO.
The findings on (unstimulated) BIS, SE, and RE are in 
agreement with that reported in previous literature. Nieu-
wenhuijs et al.12 presented an interaction model during 
sevoflurane–alfentanil anesthesia, suggesting additivity for 
BIS. During propofol anesthesia, Vanluchene et al.3 found 
that remifentanil evoked an increase in the threshold for loss 
of consciousness on BIS, SE, and RE in a dose-dependent 
way, but no conclusion was drawn on the nature of this 
interaction. Bouillon et al.13 found additivity for BIS dur-
ing propofol–remifentanil anesthesia. Schumacher et al.10 
found an additive interaction on BIS for combined propofol 
and sevoflurane. Conversely, the interaction of sevoflurane 
and remifentanil on clinical endpoints of effect, as pub-
lished by Heyse et al.,2 was not additive but synergistic. Also, 
C50REMI was 10-fold higher for BIS, SE, and RE compared 
with C50REMI for dichotomous endpoints.
2 Apparently, the 
opioid effect on the electroencephalogram is weak, despite 
a strong effect on patient responsiveness. This may explain 
why electroencephalographic variables are poor predictors of 
responsiveness to noxious stimuli.
According to the parameter estimates (table 1), BIS is 
least opioid sensitive, followed by SE, RE, and CVI, whereas 
BIS, SE, and RE are equally sensitive to sevoflurane, but less 
than CVI. The slope of the response surfaces is similar for 
BIS, SE, and RE, but steeper than the slope for CVI (fig. 5). 
The interaction model for BIS is characterized by the low-
est interindividual (table 1: IIV [C50REMI]) and residual 
variability.
Interaction models not only define combined effects of 
sevoflurane and remifentanil as a response surface but also 
allow expression of the potency of a combination of drugs as 
one dimensionless number. For this purpose, we introduced 
“U” being units of combined potency related to each of the 
investigated effects variables. For example, UBIS is the sum of 
Fig. 7. Isoboles for Composite Variability Index values of 0.5, 
1, 1.5, 2, 2.5, and 3 for the unstimulated (solid lines) and stimu-
lated (dashed lines) data, as a function of the end-tidal sevo-
flurane concentration and the predicted remifentanil  effect-site 
concentration, calculated from the data listed in table 1.
Fig. 6. Isoboles for bispectral index values of 10, 20, 30, 40, 
50, 60, 70, and 80 for the unstimulated (solid lines) and stimu-
lated (dashed lines) data, as a function of the end-tidal sevo-
flurane concentration and the predicted remifentanil  effect-site 
concentration, calculated from the data listed in table 1.
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the sevoflurane and remifentanil concentration both normal-
ized to the respective C50’s of the BIS dose–response curve 
(equations 2 and 4). The potency UBIS = 1 can be achieved 
by 1.99 vol% of sevoflurane (=C50SEVO) or (e.g.) by 1.49 
vol% of sevoflurane (=0.75 × C50SEVO) plus 6.8 ng/ml of 
remifentanil (=0.25 × C50REMI). As C50 is specific for each 
electroencephalographic variable, one given sevoflurane and 
remifentanil concentration does not yield identical values of 
“U” for BIS, SE, RE, or CVI. According to the final models 
(table 1), 1.5 vol% of sevoflurane combined with 5 ng/ml of 
remifentanil yields a UBIS, USE, URE, and UCVI of 0.94, 1.13, 
1.07, and 2.29, respectively.
In concordance with Minto et al.,11 we consider the com-
bination of two drugs as a virtual new drug. “U” can be used 
as if it was a drug concentration of that virtual new drug 
on the x-axis of a two-dimensional concentration–response 
curve (figs. 2–5). With the selected interaction models, the 
combined potency “U” predicted the effect on BIS, SE, and 
RE with an error of approximately 10%, which is compa-
rable to that reported in the previous studies.13
“U” as a number represents potency of a combination of 
sevoflurane and remifentanil to suppress the electroencephalo-
graphic variable and has similarities with the Noxious Stimu-
lation Response Index.14 The Noxious Stimulation Response 
Index is based on the suppression of a response to laryngos-
copy, using the Hierarchical interaction model. The C50REMI 
(1.16 ng/ml) in this model is much lower than the C50REMI in 
the current study (7.5 to 27.3 ng/ml, depending on the type of 
electroencephalographic variable). This makes Noxious Stim-
ulation Response Index much more opioid sensitive compared 
with “U,” which is in agreement with the fact that hypnot-
ics have a stronger effect on electroencephalogram than the 
effects of opioids on electroencephalogram. The clinical utility 
of any of the “U”s or Noxious Stimulation Response Index to 
titrate opioids and hypnotics remains to be determined.
The CVI as a potential indicator of nociception behaved 
similar as dichotomous endpoints in the previous study2: 
the interaction was synergistic. The best fit was found with 
the reduced Greco model. As expected, the concentration–
response curve of CVI was affected by noxious stimulation 
(figs. 5 and 7), especially due to a substantial increase in 
baseline effect (E0), probably due to an increase in electro-
myographic activity. The dose–response curve was rather 
flat, and a ceiling effect was observed at the level of a CVI of 
approximately 1 (fig. 5). This explains why a larger increase 
of the sevoflurane concentration is needed to lower CVI 
from 1 to 0.5 than that required to lower CVI from 3 to 2.5 
(fig. 7). Although noxious stimulation and opioids evoke a 
greater effect on CVI than on BIS, SE, and RE, CVI may 
offer lower discriminating capacity compared with BIS, 
SE, and RE. Even in our best-fitted model, the differences 
between estimated and observed CVI were high, especially 
after noxious stimulation (figs. 1 and 5).
The poststimulation data set represents a population that 
is in a pharmacological pseudosteady state (at similar drug 
concentrations as before stimulation), where the applied 
stimuli may have disrupted the balance between drug con-
centrations and effect variables. Assuming that noxious 
stimulation might induce an arousal response on the elec-
troencephalographic variables, we hypothesized that the 
parameter estimates from the poststimulation data could 
be different from those of the prestimulation data. We 
expected larger differences in model estimates for CVI and 
SPI compared with BIS, SE, and RE, as the arousal response 
in BIS is already suppressed by rather low remifentanil 
concentrations.15
For all poststimulation response surface models, the struc-
tural model with the lowest objective function was identical 
to the prestimulation model. For BIS, SE, and RE, the model 
parameters hardly changed, except for C50SEVO (consistently 
0.3 vol% higher after laryngoscopy). This pharmacodynamic 
shift is consistent for BIS and entropy and it is only little 
smaller than the difference between C50SEVO for tolerance 
of shake and shout and laryngoscopy, found in the previous 
article (0.53 vol%).2 Typical accuracy for measuring sevoflu-
rane end-tidal concentrations is ±0.15 vol% + 5% of read-
ing. The time between nonstimulation and poststimulation 
sampling did not exceed 6 min and therefore was assumed 
to be constant. Therefore, we consider 0.3 vol% (or 14% 
of 1 minimal alveolar concentration) as clinically relevant. 
The sevoflurane and remifentanil concentrations mentioned 
above (1.5 vol% and 5 ng/ml) yield a poststimulation U for 
BIS, SE, and RE which is approximately 10% lower than the 
prestimulation U. Therefore, both single-model parameters 
(e.g., C50s) and combined potency U could be used as sur-
rogate measures of stimulus intensity.
For CVI, the changes in the poststimulation model are 
complex. C50REMI decreased to 3.09 ng/ml. Gamma and 
the baseline effect (E0) increased. The increased steepness of 
the dose–response curve and the larger difference between 
baseline and maximal effect suggest an improved descriptive 
capacity for CVI in stimulated compared with unstimu-
lated conditions. However, the residual SD and the standard 
errors of the parameters indicate a larger variability in the 
dose–response relationship compared with the unstimulated 
condition. Our finding is in agreement with the notion that 
a noxious stimulus is mandatory to measure the balance 
between nociception and antinociception accurately.
For SPI, we were not able to extract plausible param-
eter estimates from our data, neither from prestimulation 
nor from poststimulation observations. Either SPI is hardly 
affected by sevoflurane and remifentanil or the inter- and 
intraindividual variability of SPI hides a minimal dose–
response relationship. The sympathetic and parasympathetic 
nerve system may be affected by many confounding factors 
apart from noxious stimulation and anesthetic drug dosages. 
The inability to detect any dose–response relationship in 
steady-state conditions, both with or without noxious stimu-
lation, lowers the expectations for SPI as a guide for titrating 
sevoflurane and remifentanil anesthesia.
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In conclusion, sevoflurane and remifentanil are additive 
on BIS and entropy, but they act synergistic on CVI. SPI is 
not correlated to drug concentrations. Noxious stimulation 
did not change structural models but increased the C50 of 
sevoflurane related to BIS and entropy, whereas a more com-
plex parameter shift was found for CVI.
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